Navigation Links
Assessing lead time of selected ovarian cancer biomarkers
Date:12/30/2009

Concentrations of the biomarkers CA125, human epididymis protein 4 (HE4), and mesothelin began to rise 3 years before clinical diagnosis of ovarian cancer, according to a new study published online December 30 in the Journal of the National Cancer Institute. However, the biomarkers became substantially elevated only in the last year prior to diagnosis. The stage of the cancer at the time of marker elevation is not known.

CA125, HE4, mesothelin, B7-H4, decoy receptor 3, and spondin-2 have been identified as potential ovarian cancer biomarkers, but their behavior in the pre-diagnostic period, with the exception of CA125, has not been evaluated previously.

In this study, Garnet L. Anderson, Ph.D., of the Division of Public Health Sciences at the Fred Hutchinson Cancer Research Center in Seattle, and colleagues analyzed stored serum samples from the Carotene and Retinol Efficacy Trial, a randomized, double-blind, placebo-controlled chemoprevention trial testing the effects of beta-carotene and retinol on lung cancer incidence among individuals at high risk for the disease. The researchers identified 34 patients who were diagnosed with ovarian cancer and had serum specimens available from the trial, as well as 70 matched control subjects.

Serum concentrations of CA125, HE4, and mesothelin began to increase slightly in cancer patients approximately 3 years before diagnosis but became substantially elevated only about a year before diagnosis.

These data suggest the presence of ovarian cancer up to 3 years before clinical diagnosis, but the likely lead time associated with these markers appears to be less than 1 year, according to the authors.

"Although these markers are not accurate enough to prompt early intervention in existing screening protocols, the multivariable regression analyses identified modest but statistically significant increases in risk associated with CA125, HE4, and mesothelin, which are consistent with many of the established epidemiological risk factors for ovarian cancer," the authors write.

In an accompanying editorial, Patricia Hartge, ScD, of the Division of Cancer Epidemiology and Genetics at the National Cancer Institute in Bethesda, Md., applauds the authors for taking the field one step closer to successful screening designs by showing that the levels of certain biomarkers do not increase early enough to be used for screening.

"The results of Anderson et al. are not the last word in serum markers or in combinations of markers," the editorialist writes. "Serum markers likely will form a key element in any screening regimen, with the lead time and other parameters of each marker or combination of markers being taken into account. The careful evaluation technique applied in the current study fits into a staged approach necessary for testing performance of early markers of disease."


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Related biology news :

1. Breakthrough made in assessing marine phytoplankton health
2. Lighting research center develops framework for assessing light pollution
3. Research identifies first method for testing, assessing drug treatments for Chagas disease
4. BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine
5. BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine
6. Ph.D. student in K-State plant pathology selected for international fellowship
7. ComCam Selected by ePortation on New Maritime Domain Awareness Project
8. M2SYS Biometric Software Solution Selected By GHG Corporation
9. UC Riverside student is 1 of only 5 persons selected for challenging Arctic expedition
10. ComCam Selected by ePortation on New Maritime Domain Awareness Project
11. Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... 8, 2017 About Voice Recognition Biometrics Voice ... it against a stored voiceprint template. Acoustic features ... and tone are compared to distinguish between individual ... as most PCs already have a microphone and ... recognition biometrics are most likely to be deployed ...
(Date:2/7/2017)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that the latest release ... flexible and award winning eClinical solution, is now available ... is a proven Software-as-a-Service (SaaS) clinical research technology platform ... also delivers an entire suite of eClinical tools to ...
(Date:2/3/2017)... 3, 2017 A new independent identity strategy ... LLP (IdSP) . Designed to fill a critical niche ... market, founding partners Mark Crego and ... just in identity expertise that span federal governments, the ... The Crego-Kephart combined expertise has a common theme born ...
Breaking Biology News(10 mins):
(Date:3/1/2017)...  Elizabeth Young and Joshua Rosenthal , PhD, ... University,s Health Workforce Speaker series. http://bit.ly/2lA6C8B ... be speaking on March 9, 2017 at the Milken ... DC at 12:00pm. The George ... speakers to examine new workforce configurations, their outcomes and ...
(Date:2/28/2017)... ... February 28, 2017 , ... Surface Plasmon Resonance (SPR) is ... optical phenomenon that is sensitive to changes in the dielectric properties of the medium ... changes in refractive index occurring up to 300 nm above the metal surface (Au) ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... MIDI, Inc. (Newark, DE) have formed a strategic partnership to develop and ... and renewable energy laboratories. These automated testing solutions will save analysis time ...
(Date:2/28/2017)... NEW YORK , Feb. 28, 2017 /PRNewswire/ ... company, announced today the formation of the Phosphorus ... and science experts chosen to advise the company ... company,s large-scale, multi-site research initiatives. Please visit ... team and initiatives. "We,ve gathered some ...
Breaking Biology Technology: